

## **Voluntary lot recall for MENJUGATE® Liquid vaccine lot # 150401**

**Attention:** Physicians, Nurse Practitioners, Walk-in Clinics, Hospitals

**Date:** March 7, 2016

---

GlaxoSmithKline (GSK), has made the decision to voluntarily recall a single lot of Menjugate vaccine, **lot #150401**, effective immediately. This recall applies only to this particular lot # which is printed in black ink on the back of the box as well as on the vaccine vial.

According to GSK, the recall decision was made as a precautionary measure on the basis of three Quebec reports of anaphylaxis. GSK has not received any additional reports. As of today's date, there have been no reports of either anaphylaxis or other adverse events following immunization (AEFIs) in Ontario that are associated with this vaccine lot.

Any doses of this lot that were administered is not considered a concern (i.e., any cases of anaphylaxis would occur immediately after the vaccine were given, therefore previously administered doses are no longer an anaphylaxis risk).

**The health unit will be following up directly with any facilities who have received vaccine from this lot # in recent orders to provide further direction for vaccine return and supply replenishment.**

As a reminder, any adverse events following any immunization should be reported to the health unit by completing the [Report of Adverse Event Following Immunization Form](#) and fax to: Attention VPD 705-726-3962.

[http://www.simcoemuskokahealth.org/Libraries/JFY\\_Health\\_Care\\_Professionals/Adverse\\_Event\\_Following\\_Immunization\\_Reporting.sflb.ashx](http://www.simcoemuskokahealth.org/Libraries/JFY_Health_Care_Professionals/Adverse_Event_Following_Immunization_Reporting.sflb.ashx)

If you have any questions please contact the Vaccine Preventable Disease Program Health Care Provider Line at 705-721-7520 or toll free at 1-877-721-7520 ext. 8806.

**Acute Care facilities – please forward to your Pharmacy**